Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
GNPX
GNPX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GNPX News
Growth Prospects for the EGFR-NSCLC Market Analyzed
3d ago
Newsfilter
Congressman Tim Moore Invests in Gene Therapy Company GNPX Amid High Volatility
Jan 09 2026
Benzinga
Genprex Advances GPX-002 Diabetes Gene Therapy Clinical Program
Jan 07 2026
NASDAQ.COM
Genprex Advances Diabetes Gene Therapy with Key Milestones Achieved in 2025
Jan 07 2026
PRnewswire
Genprex Advances Diabetes Gene Therapy with Key Milestones Achieved in 2025
Jan 07 2026
Newsfilter
Genprex Reports Positive Preliminary Results for Diabetes Gene Therapy GPX-002
Jan 06 2026
NASDAQ.COM
Genprex Reports Promising Preclinical Data for Diabetes Gene Therapy GPX-002
Jan 06 2026
NASDAQ.COM
Genprex's GPX-002 Shows Diabetes Gene Therapy Potential in Non-Human Primates
Jan 06 2026
PRnewswire
Genprex's GPX-002 Shows Diabetes Treatment Potential in Non-Human Primates
Jan 06 2026
Newsfilter
Top Congressional Traders of 2025: Moore Gains 52%, Pelosi Falls Short
Jan 06 2026
Benzinga
Congressman Invests in Lesser-Known Small Cap Lift Truck Firm
Dec 04 2025
Benzinga
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
Nov 19 2025
PRnewswire
Genprex Unveils At-The-Market Registered Direct Offering of Up to $10 Million in Accordance with Nasdaq Regulations
Oct 28 2025
Newsfilter
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
Oct 23 2025
PRnewswire
Stock Splits Scheduled for This Week (October 20 to October 24) – Keep Your Investments Active
Oct 19 2025
TipRanks
Genprex Seeks Approval to Offer 25 Million Shares of Common Stock from Selling Shareholders
Sep 12 2025
SeekingAlpha
Show More News
